DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,148,187 | +21.6% | 20,750 | +17.6% | 0.14% | +22.1% |
| Q2 2023 | $4,234,133 | -5.2% | 17,642 | -0.4% | 0.11% | -8.9% |
| Q1 2023 | $4,464,214 | -7.8% | 17,712 | -2.9% | 0.12% | -16.2% |
| Q4 2022 | $4,839,933 | +17.4% | 18,235 | +14.3% | 0.15% | +2.1% |
| Q3 2022 | $4,121,000 | +12.4% | 15,954 | +10.2% | 0.14% | +16.0% |
| Q2 2022 | $3,668,000 | +1.2% | 14,471 | +17.0% | 0.12% | +16.8% |
| Q1 2022 | $3,626,000 | -18.8% | 12,368 | -8.9% | 0.11% | -16.4% |
| Q4 2021 | $4,465,000 | -16.6% | 13,575 | -22.8% | 0.13% | -24.7% |
| Q3 2021 | $5,354,000 | +99.4% | 17,586 | +75.8% | 0.17% | +100.0% |
| Q2 2021 | $2,685,000 | +142.1% | 10,005 | +103.1% | 0.08% | +107.3% |
| Q1 2021 | $1,109,000 | -42.7% | 4,926 | -43.5% | 0.04% | -47.4% |
| Q4 2020 | $1,935,000 | +74.0% | 8,712 | +68.8% | 0.08% | +50.0% |
| Q3 2020 | $1,112,000 | +22.6% | 5,161 | +0.5% | 0.05% | +4.0% |
| Q2 2020 | $907,000 | -48.5% | 5,133 | -59.6% | 0.05% | -56.5% |
| Q1 2020 | $1,760,000 | -27.2% | 12,716 | -19.2% | 0.12% | -9.4% |
| Q4 2019 | $2,416,000 | +39.0% | 15,742 | +29.4% | 0.13% | +19.8% |
| Q3 2019 | $1,738,000 | 0.0% | 12,161 | 0.0% | 0.11% | -0.9% |
| Q2 2019 | $1,738,000 | +8.1% | 12,161 | -0.2% | 0.11% | -5.3% |
| Q1 2019 | $1,608,000 | +24.2% | 12,181 | -3.0% | 0.11% | 0.0% |
| Q4 2018 | $1,295,000 | -14.7% | 12,562 | -10.0% | 0.11% | +1.8% |
| Q3 2018 | $1,518,000 | -10.5% | 13,965 | -14.6% | 0.11% | -14.0% |
| Q2 2018 | $1,697,000 | +9.6% | 16,351 | +3.4% | 0.13% | +4.0% |
| Q1 2018 | $1,548,000 | +7.8% | 15,808 | +2.1% | 0.12% | -0.8% |
| Q4 2017 | $1,436,000 | +194.9% | 15,476 | +172.6% | 0.12% | +123.2% |
| Q3 2017 | $487,000 | -17.2% | 5,677 | -18.5% | 0.06% | -27.3% |
| Q2 2017 | $588,000 | -56.2% | 6,964 | -55.7% | 0.08% | -60.5% |
| Q1 2017 | $1,343,000 | +287.0% | 15,706 | +254.9% | 0.20% | +200.0% |
| Q3 2016 | $347,000 | -22.2% | 4,426 | +0.2% | 0.06% | -35.6% |
| Q2 2016 | $446,000 | +2873.3% | 4,417 | +2731.4% | 0.10% | +2425.0% |
| Q1 2016 | $15,000 | -96.2% | 156 | -96.4% | 0.00% | -96.9% |
| Q4 2015 | $397,000 | +15.7% | 4,277 | +6.2% | 0.13% | +23.1% |
| Q3 2015 | $343,000 | +383.1% | 4,027 | +386.9% | 0.10% | +395.2% |
| Q2 2015 | $71,000 | +1.4% | 827 | 0.0% | 0.02% | +10.5% |
| Q1 2015 | $70,000 | +1.4% | 827 | 0.0% | 0.02% | -13.6% |
| Q4 2014 | $69,000 | +11.3% | 827 | +3.4% | 0.02% | -29.0% |
| Q4 2013 | $62,000 | – | 800 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |